Individuals with kidney disease and their healthcare providers can be excused for having a love-hate relationship with anticoagulation.
Chronic kidney disease (CKD) heightens the risk of conditions that normally require anticoagulation (deep venous thrombosis, atrial fibrillation), but it also greatly increases the risk of anticoagulationrelated complications, most notably major bleeding. 1 This complicates the assessment of the risk/benefit ratio for initiating anticoagulation in individuals with CKD-particularly those with end-stage kidney disease and atrial fibrillation, for whom there is weak evidence supporting a clinical benefit from anticoagulation but a clear signal for excess risk of death and major bleeding. is important to note that the median age of the population studied was 78 years old and that the annualized difference in eGFR decline between those exposed to vitamin K antagonists versus those who were not was rather small. The long-term benefit of vitamin K antagonism with respect to avoiding significant comorbidity related to stroke or other thromboembolic events may outweigh a slightly faster rate of kidney function decline for many older patients. Shared decision-making that encompasses the priorities, values and goals of each patient is incumbent when making decisions on starting anticoagulation in CKD patients.
Posch and colleagues have provided a valuable contribution to our understanding of a potential risk associated with vitamin K antagonists in CKD patients. Whether this risk can be mitigated by using direct-acting oral anticoagulants would be of substantial clinical interest in selecting the best agent to reduce the risk of thromboembolic events while minimizing other potential risks such as loss of kidney function.
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